{
    "clinical_study": {
        "@rank": "58520", 
        "arm_group": [
            {
                "arm_group_label": "alirocumab SAR236553 (REGN727) - mild hepatic function", 
                "arm_group_type": "Experimental", 
                "description": "Injection through subcutaneous (SC) administration in patients with mild hepatic function"
            }, 
            {
                "arm_group_label": "alirocumab SAR236553 (REGN727) - moderate hepatic function", 
                "arm_group_type": "Experimental", 
                "description": "Injection through subcutaneous (SC) administration in patients with moderate hepatic function"
            }, 
            {
                "arm_group_label": "alirocumab SAR236553 (REGN727) - normal hepatic function", 
                "arm_group_type": "Experimental", 
                "description": "Injection through subcutaneous (SC) administration in patients with normal hepatic function"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      Study the effect of mild or moderate hepatic impairment on the pharmacokinetics of\n      alirocumab SAR236553 (REGN727).\n\n      Secondary Objectives:\n\n        -  Assess the safety and tolerability of alirocumab SAR236553 (REGN727) in patients with\n           mild and moderate hepatic impairment and in matched subjects with normal hepatic\n           function.\n\n        -  Assess the pharmacodynamic profile of alirocumab SAR236553 (REGN727) in patients with\n           hepatic impairment and in matched subjects with normal hepatic function."
        }, 
        "brief_title": "Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": [
                "Hypercholesterolemia", 
                "Liver Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Total duration of the study per subject (excluding screening) is about 12 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Male or female, between 18 to 75 years of age, inclusive.\n\n          -  Patients with mild and moderate hepatic impairment based on Child-Pugh score and\n             stable chronic liver disease.\n\n          -  Healthy subjects with normal hepatic function.\n\n        Exclusion criteria:\n\n          -  Patients with acute hepatitis, hepatic encephalopathy grade 2, 3, and 4.\n\n          -  Patients with history or presence of uncontrolled clinically relevant illness.\n\n          -  Healthy subjects with history or presence of clinically relevant illness.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670734", 
            "org_study_id": "POP12671", 
            "secondary_id": [
                "2012-002292-33", 
                "U1111-1129-0248"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "alirocumab SAR236553 (REGN727) - mild hepatic function", 
                "alirocumab SAR236553 (REGN727) - moderate hepatic function", 
                "alirocumab SAR236553 (REGN727) - normal hepatic function"
            ], 
            "description": "alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)\nPharmaceutical form:Solution for injection Route of administration: subcutaneous", 
            "intervention_name": "alirocumab SAR236553 (REGN727)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35000"
                    }, 
                    "name": "Investigational Site Number 250001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chisinau", 
                        "country": "Moldova, Republic of", 
                        "zip": "2025"
                    }, 
                    "name": "Investigational Site Number 498001"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Moldova, Republic of"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-Label, Pharmacokinetic and Tolerability Study of SAR236553/REGN727 Given as a Single SC Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics:  Assessment of serum concentrations of alirocumab SAR236553 (REGN727)", 
            "safety_issue": "No", 
            "time_frame": "Up to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670734"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assessment of PK parameter - terminal elimination half-life (t1/2z) [", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Assessment of PK parameter - apparent total body clearance  (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Assessment of PK parameter - Distribution volume at the steady-state  (Vss/F)", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Assessment of PK parameter - time to maximum concentration (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Assessment of PK parameter - Mean Residence Time (MRT [area])", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Pharmacodynamics: Change in LDL-C from baseline", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Number of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}